Compare GLP-1 Therapies in India
Side-by-side breakdowns of the leading semaglutide and tirzepatide options available in India in 2026 — efficacy, side effects, and price compared at both brand and molecule level.
Not sure where to start?
The 5-minute Indian-guideline assessment recommends a starting point based on your profile.
Ozempic vs Wegovy
Ozempic vs Wegovy in India — Which One Do You Actually Need?
Both are Novo Nordisk’s semaglutide and pharmacologically identical, but they are NOT interchangeable in India. Ozempic is DCGI-approved for type 2 diabetes (max weekly dose 2 mg), Wegovy is approved for chronic weight management (titrated up to 2.4 mg). If your goal is weight loss without diabetes, Wegovy is the on-label choice. If you have T2D, Ozempic is on-label and often cheaper.
Mounjaro vs Wegovy
Mounjaro vs Wegovy in India — Which Loses More Weight?
Mounjaro (tirzepatide, Eli Lilly) and Wegovy (semaglutide, Novo Nordisk) are the two highest-efficacy weight-loss injectables available in India. Mounjaro is a dual GIP/GLP-1 receptor agonist that produces ~22.5% body weight reduction at 15 mg over 72 weeks (SURMOUNT-1). Wegovy is a pure GLP-1 agonist producing ~14.9% at 2.4 mg over 68 weeks (STEP-1). Mounjaro generally wins on raw efficacy; Wegovy has longer real-world safety data.
Ozempic vs Mounjaro
Ozempic vs Mounjaro in India — For Diabetes and Weight
Both Ozempic (semaglutide) and Mounjaro (tirzepatide) are DCGI-approved for type 2 diabetes in India, and both also produce significant weight loss. Mounjaro’s dual GIP/GLP-1 mechanism delivers larger HbA1c reductions (1.9–2.6% vs Ozempic’s 1.4–1.8%) and roughly twice the weight loss at maximum dose. Ozempic is approximately half the price. The choice often comes down to diabetes control goals, weight-loss target, and budget.
Semaglutide vs Tirzepatide
Semaglutide vs Tirzepatide in India — Class-Level Comparison
Semaglutide is a single-agonist GLP-1 receptor drug; tirzepatide is a dual GIP/GLP-1 agonist. In India, semaglutide is available as Ozempic, Wegovy, Rybelsus, and 10+ Indian generic brands; tirzepatide is currently only available as Mounjaro. Tirzepatide produces ~50% more weight loss on average (~22% vs ~15% at maximum doses) but costs 3–5× more in India. The molecule choice is mechanism-vs-cost, with the brand choice within each class adding further variability.
Information based on DCGI-approved labelling and peer-reviewed clinical trials. Always consult a qualified medical practitioner before starting or switching therapy.